368 related articles for article (PubMed ID: 7286593)
1. Effects of immunosuppressive therapy on viral markers in chronic active hepatitis B.
Scullard GH; Smith CI; Merigan TC; Robinson WS; Gregory PB
Gastroenterology; 1981 Dec; 81(6):987-91. PubMed ID: 7286593
[TBL] [Abstract][Full Text] [Related]
2. Effect of short-term prednisone therapy on aminotransferase levels and hepatitis B virus markers in chronic type B hepatitis.
Rakela J; Redeker AG; Weliky B
Gastroenterology; 1983 May; 84(5 Pt 1):956-60. PubMed ID: 6832570
[TBL] [Abstract][Full Text] [Related]
3. Adenine arabinoside therapy in HBsAg-positive chronic liver disease: a controlled study.
Bassendine MF; Chadwick RG; Salmeron J; Shipton U; Thomas HC; Sherlock S
Gastroenterology; 1981 May; 80(5 pt 1):1016-22. PubMed ID: 7009310
[TBL] [Abstract][Full Text] [Related]
4. [Immunosuppressive treatment of patients with chronic active HBsAg positive hepatitis].
Tanno H; Fay O; Roldán L; Vorovioff J
Acta Gastroenterol Latinoam; 1982; 12(4):323-32. PubMed ID: 7185230
[TBL] [Abstract][Full Text] [Related]
5. [Surface antigen (HBsAg) and core antibody (anti-HBc) in chronic uremia during periodic hemodialysis treatment of hepatitis B patients. Correlation with viral replication markers (HBeAg and DNA polymerase activity)].
Buongiorno R; Dentico P; Santantonio T; Frappampina V; Spinelli A; Amato M; Pastore G
Boll Soc Ital Biol Sper; 1980 Oct; 56(20):2076-82. PubMed ID: 7459119
[TBL] [Abstract][Full Text] [Related]
6. [Immunosuppressive therapy in patients with HBeAg-positive chronic active hepatitis B?].
Maier KP; Lepiorz H; Berthold H; Gerok W
Leber Magen Darm; 1982 Aug; 12(4):150-3. PubMed ID: 7132529
[TBL] [Abstract][Full Text] [Related]
7. [Hepatopathy and hepatitis B virus infection in dialysis patients: cross-sectional study].
Fabrizi F; Bisegna S; Mangano S; Alongi G; Colucci P; Finazzi S; De Vecchi AF; Ponticelli C
G Ital Nefrol; 2002; 19(2):149-54. PubMed ID: 12195413
[TBL] [Abstract][Full Text] [Related]
8. Persistence of hepatitis B virus DNA in the liver after loss of HBsAg in chronic hepatitis B.
Fong TL; Di Bisceglie AM; Gerber MA; Waggoner JG; Hoofnagle JH
Hepatology; 1993 Dec; 18(6):1313-8. PubMed ID: 8244254
[TBL] [Abstract][Full Text] [Related]
9. Effects of immunosuppressive therapy on hepatic expression of hepatitis B viral genome and gene products.
Lau JY; Bird GL; Alexander GJ; Williams R
Clin Invest Med; 1993 Jun; 16(3):226-36. PubMed ID: 8365050
[TBL] [Abstract][Full Text] [Related]
10. A pilot study of long-term weekly interferon-beta administration for chronic hepatitis B.
Kagawa T; Morizane T; Saito H; Tsunematsu S; Tada S; Kumagai N; Tsuchimoto K; Sugiura H; Mukai M; Tsuchiya M
Am J Gastroenterol; 1993 Feb; 88(2):212-6. PubMed ID: 8424423
[TBL] [Abstract][Full Text] [Related]
11. Pilot study of ribavirin and interferon-beta for chronic hepatitis B.
Kakumu S; Yoshioka K; Wakita T; Ishikawa T; Takayanagi M; Higashi Y
Hepatology; 1993 Aug; 18(2):258-63. PubMed ID: 8340055
[TBL] [Abstract][Full Text] [Related]
12. Immunosuppressive therapy in chronic liver disease.
Sherlock S
Minerva Med; 1978 Aug; 69(38):2605-9. PubMed ID: 714260
[TBL] [Abstract][Full Text] [Related]
13. Randomized controlled trial of adenine arabinoside monophosphate for chronic type B hepatitis.
Hoofnagle JH; Hanson RG; Minuk GY; Pappas SC; Schafer DF; Dusheiko GM; Straus SE; Popper H; Jones EA
Gastroenterology; 1984 Jan; 86(1):150-7. PubMed ID: 6196251
[TBL] [Abstract][Full Text] [Related]
14. [Usefulness of the determination of DNA polymerase activity of hepatitis B virus in chronic HBsAg carriers].
Carreño García V; Porres Cubero JC; Mora Pérez I; Hernańdez Guío C
Rev Clin Esp; 1984 Aug 15-31; 174(3-4):75-7. PubMed ID: 6515078
[No Abstract] [Full Text] [Related]
15. Effects of human leucocyte interferon on hepatitis B virus replication and immune responses in patients with chronic hepatitis B infection.
Scullard GH; Alberti A; Wansbrough-Jones MH; Howard CR; Eddleston AL; Zuckerman AJ; Cantell K; Williams R
J Clin Lab Immunol; 1979 Feb; 1(4):277-82. PubMed ID: 501726
[TBL] [Abstract][Full Text] [Related]
16. Combination therapy of glycyrrhizin withdrawal and human fibroblast interferon for chronic hepatitis B.
Hayashi J; Kashiwagi S; Noguchi A; Ikematsu H; Tsuda H; Tsuji Y; Motomura M
Clin Ther; 1989; 11(1):161-9. PubMed ID: 2497983
[TBL] [Abstract][Full Text] [Related]
17. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
18. Treatment of chronic active hepatitis (CAH): a retrospective review of 130 patients.
Giusti G; Ruggiero G; Galanti B; Piccinino F; Russo M; Galante D; Sagnelli E; Utili R; Pasquale G; Nardiello S; Aloisio V
Hepatogastroenterology; 1981 Oct; 28(5):245-9. PubMed ID: 7047337
[TBL] [Abstract][Full Text] [Related]
19. A molecular analysis of viral persistence in surface antigen-negative chronic hepatitis B.
Kato J; Hasegawa K; Torii N; Yamauchi K; Hayashi N
Hepatology; 1996 Mar; 23(3):389-95. PubMed ID: 8617416
[TBL] [Abstract][Full Text] [Related]
20. Correlation of hepatocyte expression of hepatitis B viral antigens with histological activity and viral titer in chronic hepatitis B virus infection: an immunohistochemical study.
Ramakrishna B; Mukhopadhya A; Kurian G
J Gastroenterol Hepatol; 2008 Nov; 23(11):1734-8. PubMed ID: 18713304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
